Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma

NCT01798485 is registered in ClinicalTrials.gov with Synta Pharmaceuticals Corp. as lead sponsor.

NCT NCT01798485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01798485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma
Lead sponsor
Synta Pharmaceuticals Corp.
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2013
Completion date
December 31, 2015
Enrollment
696 (actual)
Sites
267

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic, non-small cell lung cancer stage iiib, non-small cell lung cancer stage iv, non-small-cell lung adenocarcinoma